A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Completed · Phase 1

Conditions studied: Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer

In brief

The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated.

Key facts

Study ID

NCT00730639

Run by

Bristol-Myers Squibb

People needed

395

Starts

2008-10-30

Expected to finish

2020-12-22

Last updated by the study team

2021-12-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have mCRPC,RCC, MEL, Non-small-cell lung cancer (NSCLC), or Colorectal Cancer (CRC), that is advanced (non-resectable), or recurrent and for which no alternative, curative standard exists
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
• Must have at least 1 measurable lesion
• Subjects with mCRPC and with only non-measurable bone lesions must have either progression new lesions or have Prostate-specific antigen (PSA) progression within the 6-week period before study administration
• At least 1 and up to 5 prior systemic therapies for advanced/recurrent disease
• Prior treated brain or meningeal metastases must be without Magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off immunosuppressive doses of systemic steroids for at least 2 weeks before study drug administration
• Prior systemic radiation therapy must have been completed at least 4 weeks before study drug administration. Prior focal radiotherapy completed at least 2 weeks prior to study drug administration
• Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids must be discontinued at least 2 weeks before study drug administration
• Prior surgery that required general anesthesia must be completed at least 2 weeks before study drug administration. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration

You may not qualify if…

• History of severe hypersensitivity reactions to other Monoclonal antibody (mAb)s
• Subjects with any active autoimmune disease or a documented history of autoimmune disease, or history of syndrome that required systemic steroids or immunosuppressive medications, except for subjects with vitiligo or resolved childhood asthma/atopy
• Prior therapy with an anti-Programmed death-1 (PD-1), anti-PD-L1, anti-PD-L2, or anti- Cytotoxic t-lymphocyte antigen-4 (CTLA-4) antibody (or any other antibody targeting T cell co-stimulation pathways)
• Known history of Human Immunodeficiency Virus
• Active infection requiring therapy, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA)
• Underlying medical conditions that will make the administration of study drug hazardous
• Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids
• Use of other investigational drugs (drugs not marketed for any indication) within 28 days or at least 5 half-lives (whichever is longer) before study drug administration

Where it is running

• Pinnacle Oncology Hematology — Scottsdale, Arizona, United States
• Yale University School Of Medicine — New Haven, Connecticut, United States
• H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• University Of Michigan Cancer Center — Ann Arbor, Michigan, United States
• Memorial Sloan Kettering Nassau — New York, New York, United States
• Carolina Biooncology Institute — Huntersville, North Carolina, United States
• Christ Hospital — Cincinnati, Ohio, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Vanderbilt-Ingram Cancer Ctr — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.